Our aim is to characterize the functional properties of circulating cells (monocytes, lymphocytes, and progenitor cells) in patients with chronic coronary artery disease (CAD) and acute myocardial infarction (AMI). Likewise, we wish to characterize…
ID
Source
Brief title
Condition
- Coronary artery disorders
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Possible differences between the study groups in number, phenotype or function
will be statistically analyzed.
Secondary outcome
not applicable
Background summary
Occlusion of a coronary artery leads to ischemia and to the consecutive death
of myocytes and vascular structures in the supplied region of the heart. The
development of new blood vessels in response to tissue ischemia constitutes a
natural repair mechanism that maintains tissue perfusion required for proper
organ function. The functional recovery of myocardium is partly dependent on
the formation of new blood vessels to supply oxygen and nutrients to
myocardium. Different cardiovascular risk factors such as diabetes mellitus
alter structure and function of existing blood vessels (atherogenesis) and
impair the formation of new ones (angiogenesis). For this reason, many
experimental and clinical therapies have mainly focused on understanding how to
overcome the negative influence of diabetes mellitus and how to limit
myocardial ischemia by stimulating the formation of new blood vessels. This
process of vascular growth is facilitated by monocytes, lymphocytes and bone
marrow-derived progenitor cells. The proper function of these cells is
important. Cardiovascular risk factors such as diabetes mellitus can negatively
influence the function of these cells.
Study objective
Our aim is to characterize the functional properties of circulating cells
(monocytes, lymphocytes, and progenitor cells) in patients with chronic
coronary artery disease (CAD) and acute myocardial infarction (AMI). Likewise,
we wish to characterize the role of diabetes mellitus (DM) on cellular
function, both independent of CAD and together.
Study design
Blood samples (100 ml) will be collected from subjects by venupuncture.
Monocytes, lymphocytes and progenitor cells will be specifically isolated.
Cells will be characterized for their number and phenotypic characteristics. In
addition, they will be subjected to functional assays including a chemotaxis
assay to analyze their response towards various growth factors.
Study burden and risks
Research methods are minimally invasive, therefore there is a neglijible risk
for the patients.
Relevance for medicine: These data will help to better understand the process
of vascular repair and vascular growth in patients with coronary
atherosclerosis. Moreover, it will provide valuable information on the role of
cardiovascular risk factors such as diabetes on the process of vascular growth.
This will represent a solid background for the development of novel
anti-atherosclerotic therapies.
P.Debeyelaan 25
6202AZ Maastricht
Nederland
P.Debeyelaan 25
6202AZ Maastricht
Nederland
Listed location countries
Age
Inclusion criteria
•Diabetes mellitus: Diabetes type II, compensated with diet and/or oral medication.
•CAD: History of coronary artery disease >2 years, no myocardial infarction in the last 6 months.
•AMI: >3-fold increase of CK (CK-MB) levels. Patients with coronary artery disease in their early period after Acute Myocardial Infarction (day 4 - 7 post-infarction) will be recruited.
•Controls: patients diagnosed with hypertension, arrhythmias and/or heart valvular diseases; subjects should be age-matched with the above mentioned groups (subjects <45 years or >75 years old will be excluded).
Exclusion criteria
•Anemia (Hb<8 g/L)
•Acute infectious diseases (e.g., pneumonia, urinary tract infections, anaphylactic shock etc.)
•Acute inflammation other than AMI (elevated leukocyte number)
•Acute conditions (surgery, stroke, thromboembolism etc)
•Single or multiorgan failure (heart failure NYHA III/IV, lung, liver, kidneys)
•Chronic inflammatory diseases (chronic kidney diseases, rheumatoid arthritis)
•Malignant diseases (or recent history of malignant diseases <1 year)
•Malignant arterial hypertension
•Hormonal treatment (thyroid hormones-T3/T4 not included) or anti-inflammatory drugs
•Genetic disorders (Down syndrome, X&Y chromosome syndrome), family hypercholesterolemia, genetic dyslipidemia
•Psychiatric abnormalities
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL17185.068.07 |